

REMARKS

In response to the Restriction Requirement mailed 3 June 2003, Paper No. 13, Applicants hereby elect, without traverse, for part A (heterologous molecule of interest) the species drawn to a polypeptide as recited in claim 13. Further, Applicants wish to elect the following subspecies: a recombinant molecule of the major histocompatibility complex as recited in claim 14, a class II molecule of the major histocompatibility complex as recited in claim 53, and the DR1 serotype as recited in claim 56 for prosecution in the subject application. Applicants submit that claims 52, 53, 54, 55, 56, 58 as well as newly added claim 59 are readable on the elected species.

Applicants, of course, reserve the right to file divisional applications directed to the subject matter of the non-elected claims.

New claim 59 has been added. Support for newly added claim 59 may be found throughout the specification. It is submitted that no new matter has been introduced by the present amendments and entry of the same is respectfully requested. By the present amendments and new claim, Applicants do not acquiesce to the propriety of any of the Examiner's rejections and do not disclaim any subject matter to which the Applicants are entitled. *Cf. Warner-Jenkinson Co. v. Hilton Davis Chem. Co.*, 41 U.S.P.Q.2d 1865 (U.S. 1997).

If there are any further fees due in connection with the filing of the present reply, please charge the fees to undersigned's Deposit Account No. 50-1067. If a fee is required for an extension of time not accounted for, such an extension is requested and the fee should also be charged to undersigned's deposit account.

Respectfully submitted,

2 July 2003



Don J. Pelto
Reg. No. 33,754

LAURENCE SUNE
38,330

Preston Gates Ellis & Rouvelas Meeds LLP
1735 New York Ave, NW, Suite 500
Washington, DC 20006
Telephone: (202) 628-1700
Facsimile: (202) 331-1024